FRAX®工具可预测慢性肾脏病患者的骨折风险
本研究基于Manitoba骨密度数据库,纳入10,099名未透析成人,评估FRAX®对CKD患者骨折风险的预测能力。结果显示FRAX在全部eGFR分层中均可预测主要骨质疏松性骨折和髋部骨折,支持其用于非透析CKD患者的风险分层。
要点
- FRAX®在CKD各期均可预测主要骨质疏松性骨折和髋部骨折风险。
- 随FRAX评分(含BMD)每增加1个标准差,髋部骨折风险在各eGFR层均显著升高。
- FRAX与主要骨质疏松性骨折的关系在CKD患者中比eGFR保留者更强。
核心结论
- FRAX®可用于非透析CKD患者的主要骨质疏松性骨折和髋部骨折风险分层。
研究设计与样本
- 基于Manitoba骨密度数据库的队列研究,纳入10,099名未透析且1年内有血肌酐和骨密度测定的成人。
- 平均年龄64±13岁,男性占13.0%;eGFR 30-60 mL/min/1.73 m2者2,154例,eGFR<30 mL/min/1.73 m2者590例。
- 观察期5年,结局为主要骨质疏松性骨折和髋部骨折,取自人群健康数据库。
主要发现
- 5年观察期间,772人发生主要骨质疏松性骨折,226人发生髋部骨折。
- FRAX(含BMD)评分每增加1个标准差,髋部骨折HR在eGFR≥60组为4.54(95%CI 3.57-5.77),eGFR 30-60组为4.52(95%CI 3.15-6.49),eGFR<30组为3.10(95%CI 1.80-5.33)。
- FRAX与主要骨质疏松性骨折的关系在CKD患者中比eGFR保留者更强。
临床怎么用
- 对非透析CKD患者可使用FRAX®评估主要骨质疏松性骨折和髋部骨折风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Fracture Risk Assessment Tool (FRAX®) was developed to predict fracture risk in the general population, but its applicability to patients with chronic kidney disease (CKD) is unknown. Using the Manitoba Bone Mineral Density (BMD) Database, we identified adults not receiving dialysis with available serum creatinine measurements and bone densitometry within 1 year. Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. Incident major osteoporotic fractures and hip fractures were ascertained from population-based health care databases. The performance of FRAX, derived without and with BMD, was studied in relation to CKD stage. Among 10,099 subjects (mean age 64 ± 13 years, 13.0% male), 2,154 had eGFR 30-60 mL/min/1.73 m2 (CKD stage 3) and 590 had eGFR <30 mL/min/1.73 m2 (CKD stages 4-5). During a 5-year observation period, 772 individuals experienced a major osteoporotic fracture and 226 had a hip fracture. FRAX predicted risk for major osteoporotic fracture and hip fracture in all eGFR strata. For every standard deviation increase in FRAX score derived with BMD, the hazard ratio (HR) for hip fracture was 4.54 (95% confidence interval [CI] 3.57-5.77) in individuals with eGFR ≥ 60 mL/min/1.73m2, 4.52 (95% CI 3.15-6.49) in individuals with eGFR 30-60 mL/min/1.73m2, and 3.10 (95% CI 1.80-5.33) in individuals with eGFR <30 mL/min/1.73m2. The relationship between FRAX and major osteoporotic fracture was stronger in those with CKD compared to those with preserved eGFR. These findings support the use of FRAX to risk stratify patients with non-dialysis CKD for major osteoporotic fractures and hip fractures.
引用
- Whitlock RH, Leslie WD, Shaw J, et al. The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. Kidney Int. 2018. PMID: 30579724. doi:10.1016/j.kint.2018.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。